S&P Futures
4,161.75 +31.25 (+0.76%) Dow Futures
34,209.00 +214.00 (+0.63%) Nasdaq Futures
12,685.00 +139.75 (+1.11%) Russell 2000 Futures
1,963.90 +14.00 (+0.72%) Crude Oil
78.56 +0.09 (+0.11%) Gold
1,894.20 +3.50 (+0.19%)
Morphic Holding, Inc. (MORF)
After hours:
Chart Events
Performance Outlook
| Previous Close | 36.81 |
| Open | 36.75 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 35.75 - 37.68 |
| 52 Week Range | 19.23 - 46.72 |
| Volume | |
| Avg. Volume | 236,368 |
| Market Cap | 1.405B |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.88 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MORF
Related Research
- Morphic Holding, Inc.Daily – Vickers Top Buyers & Sellers for 10/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- American City Business Journals
The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug
Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.
- Zacks
Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- GlobeNewswire
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST. A live webcast of the presentation will be available on the Investor section of Morphic’s
